Iberdomide Combination Therapy Doubles MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma

Results from the Phase 3 EXCALIBER-RRMM trial, published in The Lancet Oncology, indicate that a combination therapy of iberdomide, daratumumab, and dexamethasone more than doubled the rate of minimal residual disease (MRD)-negative complete response compared to standard therapy in patients with relapsed or refractory multiple myeloma. This finding suggests a significant improvement in treatment outcomes for this patient population.